Skip to main content
Premium Trial:

Request an Annual Quote

UC and Springer Nature Reach Deal

The University of California and scientific publisher Springer Nature have reached a deal on open-access publishing.

Under a four-year agreement, UC research published in Springer Nature journals will be open access, and UC students, faculty, and researchers will have access to more than 1,000 Springer Nature journals, including ones to which UC did not previously subscribe. At the same time, UC and Springer Nature are to launch an open science pilot project. 

According to the Financial Times, this is the largest open-access agreement in North America. It adds that how much UC will pay will depend on the number of articles published, but that the university system estimates that it will bring down its costs.

"UC has always believed that providing greater open access to knowledge is the right thing to do. Springer Nature showed us that it can be done," Jeffrey MacKie-Mason, a librarian and economics professor at UC Berkeley who co-chaired the publisher negotiation team, says in a statement.

Last year, the University of California ended its subscription contract negiotiations with Elsevier, as it sought a "read-and-publish" contract that combined journal subscription and open-access publishing fees, but Elsevier wanted to maintain its traditional contract. MIT last week similarly ended negotiations with Elsevier.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more